Molecular Insights into Identification of Natural AKT1/mTOR Signaling Inhibitors from Veratrum Viride-Derived Alkaloids for Breast Cancer Treatment: A Comprehensive Analysis Using Network Pharmacology, Molecular Docking, and Molecular Dynamics.
{"title":"Molecular Insights into Identification of Natural AKT1/mTOR Signaling Inhibitors from Veratrum Viride-Derived Alkaloids for Breast Cancer Treatment: A Comprehensive Analysis Using Network Pharmacology, Molecular Docking, and Molecular Dynamics.","authors":"Anu Priya Eswaran, Selvaraj Jayaraman, Sathan Raj Natarajan, Vishnu Priya Veeraraghavan","doi":"10.31557/APJCP.2026.27.4.1335","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Breast cancer (BC) is a complex illness that affects millions of women globally. As its incidence rises, new treatment strategies are needed. Veratrum viride, a traditional medicinal herb, is known for its therapeutic potential, yet its molecular mechanism of action against BC remains unclear. The purpose of this preliminary investigation is to assess V. viride's anti-breast cancer potential by identifying its active compounds and using bioinformatics techniques to clarify their multi-target mechanisms.</p><p><strong>Materials & methods: </strong>Initially, eleven compounds from V. viride were examined for pharmacokinetic and toxicity characteristics. Network pharmacology was used to predict and integrate compound-target interactions with genes linked to BC. Topological and drug-protein interaction (DPI) analyses were employed to identify important hub genes. KEGG pathway enrichment and Gene Ontology (GO) analyses were conducted to validate functional relevance. Target-compound interactions were verified through molecular docking and molecular dynamics simulation analysis.</p><p><strong>Results: </strong> Using ADMET profiling analysis and drug-likeness properties, three alkaloids namely jervine, veratramine, and rubijervine were identified as promising drug candidates. We identified six important hub genes: MTOR, INSR, FOXO1, FOXO3, RPS6KB1, and AKT1. According to GO and KEGG analyses, the compounds targeted pathways important in the regulation of BC, including AMPK, HIF-1, FOXO, and PI3K/AKT/mTOR. Moreover, jervine demonstrated robust binding stability and affinity with core targets in molecular docking and dynamics simulations.</p><p><strong>Conclusion: </strong>This work provides the first evidence that alkaloids derived from V. viride, especially jervine, may act as multi-target inhibitors against BC. However, further experimental validation is required to confirm their therapeutic efficacy.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 4","pages":"1335-1350"},"PeriodicalIF":0.0000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Pacific Journal of Cancer Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31557/APJCP.2026.27.4.1335","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Breast cancer (BC) is a complex illness that affects millions of women globally. As its incidence rises, new treatment strategies are needed. Veratrum viride, a traditional medicinal herb, is known for its therapeutic potential, yet its molecular mechanism of action against BC remains unclear. The purpose of this preliminary investigation is to assess V. viride's anti-breast cancer potential by identifying its active compounds and using bioinformatics techniques to clarify their multi-target mechanisms.
Materials & methods: Initially, eleven compounds from V. viride were examined for pharmacokinetic and toxicity characteristics. Network pharmacology was used to predict and integrate compound-target interactions with genes linked to BC. Topological and drug-protein interaction (DPI) analyses were employed to identify important hub genes. KEGG pathway enrichment and Gene Ontology (GO) analyses were conducted to validate functional relevance. Target-compound interactions were verified through molecular docking and molecular dynamics simulation analysis.
Results: Using ADMET profiling analysis and drug-likeness properties, three alkaloids namely jervine, veratramine, and rubijervine were identified as promising drug candidates. We identified six important hub genes: MTOR, INSR, FOXO1, FOXO3, RPS6KB1, and AKT1. According to GO and KEGG analyses, the compounds targeted pathways important in the regulation of BC, including AMPK, HIF-1, FOXO, and PI3K/AKT/mTOR. Moreover, jervine demonstrated robust binding stability and affinity with core targets in molecular docking and dynamics simulations.
Conclusion: This work provides the first evidence that alkaloids derived from V. viride, especially jervine, may act as multi-target inhibitors against BC. However, further experimental validation is required to confirm their therapeutic efficacy.
期刊介绍:
Cancer is a very complex disease. While many aspects of carcinoge-nesis and oncogenesis are known, cancer control and prevention at the community level is however still in its infancy. Much more work needs to be done and many more steps need to be taken before effective strategies are developed. The multidisciplinary approaches and efforts to understand and control cancer in an effective and efficient manner, require highly trained scientists in all branches of the cancer sciences, from cellular and molecular aspects to patient care and palliation.
The Asia Pacific Organization for Cancer Prevention (APOCP) and its official publication, the Asia Pacific Journal of Cancer Prevention (APJCP), have served the community of cancer scientists very well and intends to continue to serve in this capacity to the best of its abilities. One of the objectives of the APOCP is to provide all relevant and current scientific information on the whole spectrum of cancer sciences. They aim to do this by providing a forum for communication and propagation of original and innovative research findings that have relevance to understanding the etiology, progression, treatment, and survival of patients, through their journal. The APJCP with its distinguished, diverse, and Asia-wide team of editors, reviewers, and readers, ensure the highest standards of research communication within the cancer sciences community across Asia as well as globally.
The APJCP publishes original research results under the following categories:
-Epidemiology, detection and screening.
-Cellular research and bio-markers.
-Identification of bio-targets and agents with novel mechanisms of action.
-Optimal clinical use of existing anti-cancer agents, including combination therapies.
-Radiation and surgery.
-Palliative care.
-Patient adherence, quality of life, satisfaction.
-Health economic evaluations.